The ongoing impact of COVID-19 on health services across Europe has led to significant reductions in cancer screening, testing and diagnosis. Delays in diagnosis are already impacting cancer treatment and survival and are likely to continue for years to come. Responses to the pandemic have differed within individual countries and for specific tumour groups, with some countries responding exceptionally well under the circumstances. Emerging from the clamor are examples of best practices that provide the basis for further discussion.

This webinar will highlight:

• The significance of identifying and sharing these effective approaches to minimise the negative collateral impact of the COVID-19 pandemic on cancer screenings and testing
• The importance of building resilience into health systems for longer-term advancement of cancer care

This session will follow the release of a report by the IQVIA Institute for Human Data Science on the same topic, which is available without charge as a public service.

Speakers and panelists

Alfonso Aguaron, Patient Advocate

Antonella Cardone, Director, European Cancer Patient Coalition

Dr. Fatima Cardosa, Champalimaud Clinical Centre

Dr. Vivek Muthu, International Brain Tumour Alliance

Dr. Josep Tabernero, Vall d'Hebron University Hospital (HUVH)

Murray Aitken, Executive Director, IQVIA Institute for Human Data Science

Emma Moore, Head of Market Research & Consultancy, IQVIA

Agenda

Welcome and Introduction: Murray Aitken, Executive Director, IQVIA Institute for Human Data Science Summary of key research findings: Emma Moore, Head of Market Research & Consultancy, IQVIA Panel discussion